OverviewSuggest Edit

Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action. ... Show more
TypePublic
Founded2007
HQHellerup, DK
Websiteascendispharma.com

Latest Updates

Employees (est.) (Sep 2017)101
Job Openings18
Share Price (Feb 2019)$73.4 (+5%)

Key People/Management at Ascendis Pharma

Jan Møller Mikkelsen

Jan Møller Mikkelsen

President and CEO
Flemming Steen Jensen

Flemming Steen Jensen

President and CEO
Michael Wolff Jensen

Michael Wolff Jensen

President and CEO
Thomas A. Larson

Thomas A. Larson

President and CEO
Jonathan Leff

Jonathan Leff

Senior Vice President, Chief Financial Officer
Kennett Sprogøe

Kennett Sprogøe

Senior Vice President, Chief Financial Officer
Show more

Ascendis Pharma Office Locations

Ascendis Pharma has offices in Hellerup, Palo Alto and Heidelberg
Hellerup, DK (HQ)
5 Tuborg Blvd.
Heidelberg, DE
584 Im Neuenheimer Feld
Palo Alto, US
394 University Ave
Show all (3)
Report incorrect company information

Ascendis Pharma Financials and Metrics

Ascendis Pharma Revenue

Market capitalization (15-Feb-2019)

3.1b

Closing stock price (15-Feb-2019)

73.4
Ascendis Pharma's current market capitalization is $3.1 b.
Show all financial metrics
Report incorrect company information

Ascendis Pharma News and Updates

Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

TransCon PTH is designed to provide parathyroid hormone in the physiologic range for 24 hours each day as a true replacement therapy for hypoparathyroidism TransCon PTH is designed to provide parathyroid hormone in the physiologic range for 24 hours each day as a true replacement therapy for hypopar…

Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon ™ technology -

Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences

COPENHAGEN, Denmark, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced upcoming presentations related to its technology platform and rare e…

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Aug. 31, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will participate in three upcoming investor conferenc…

Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results

- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon ™ technology in a new therapeutic area -
Show more
Report incorrect company information

Ascendis Pharma Company Life and Culture

Report incorrect company information

Ascendis Pharma Frequently Asked Questions

  • When was Ascendis Pharma founded?

    Ascendis Pharma was founded in 2007.

  • Who are Ascendis Pharma key executives?

    Ascendis Pharma's key executives are Jan Møller Mikkelsen, Flemming Steen Jensen and Michael Wolff Jensen.

  • How many employees does Ascendis Pharma have?

    Ascendis Pharma has 101 employees.

  • Who are Ascendis Pharma competitors?

    Competitors of Ascendis Pharma include Keryx Biopharmaceuticals, NovaBay Pharmaceuticals and Chiasma.

  • Where is Ascendis Pharma headquarters?

    Ascendis Pharma headquarters is located at 5 Tuborg Blvd., Hellerup.

  • Where are Ascendis Pharma offices?

    Ascendis Pharma has offices in Hellerup, Palo Alto and Heidelberg.

  • How many offices does Ascendis Pharma have?

    Ascendis Pharma has 3 offices.